Jame Wei | Rheumatology | Best Researcher Award

Posted on by sciencefatherLeave a Comment on Jame Wei | Rheumatology | Best Researcher Award

Prof. James Wei | Rheumatology | Best Researcher Award

Prof. James Wei, Chung Shan Medical University Hospital, China Medical University, Taiwan.

Dr. James Cheng-Chung Wei, MD, PhD, FACR, is a distinguished clinical immunologist, rheumatologist, and researcher. He serves as a Professor at the Institute of Medicine, Chung Shan Medical University, and Vice Superintendent of Chung Shan Medical University Hospital. Renowned for his expertise in ankylosing spondylitis, clinical trials, and big data research, Dr. Wei has published over 600 peer-reviewed articles, amassing 15,000+ citations and an H-index of 45. He is Editor-in-Chief of the International Journal of Rheumatic Diseases and actively collaborates with global organizations like GRAPPA and ACR. His work significantly advances rheumatology and translational medicine.

Author Profile:

🎓 Education Background:

Dr. James Cheng-Chung Wei, MD, PhD, FACR, pursued his medical degree and PhD with a focus on immunology and rheumatology, laying the foundation for his illustrious career in translational medicine. His advanced training included specialized programs in clinical immunology and rheumatology, equipping him with expertise in managing complex autoimmune disorders. Dr. Wei’s academic journey was complemented by rigorous research training, which honed his skills in conducting high-impact clinical trials and big data studies. His commitment to excellence in education has shaped his role as a leading academician and researcher, contributing significantly to global advancements in medical science.

💼 Professional Experience:

Dr. James Cheng-Chung Wei, MD, PhD, FACR, has an illustrious professional career as a clinical immunologist, rheumatologist, and academic leader. He is a Professor at the Institute of Medicine, Chung Shan Medical University, and Vice Superintendent of Chung Shan Medical University Hospital. Dr. Wei has conducted over 200 global clinical trials and has served in scientific advisory roles for renowned organizations like GRAPPA, ASAS, and the American College of Rheumatology. As Editor-in-Chief of the International Journal of Rheumatic Diseases and an editorial board member of prestigious journals, he has significantly influenced research and clinical practice in rheumatology worldwide.

🌍Research Contributions:

Dr. James Cheng-Chung Wei has made groundbreaking research contributions in rheumatology, immunology, and translational medicine. With a focus on ankylosing spondylitis, he has advanced the understanding of its pathogenesis and treatment. Dr. Wei has conducted over 200 global clinical trials, pioneering evidence-based therapies that have transformed patient care. His expertise in big data studies has led to innovative approaches in real-world evidence research. With over 600 peer-reviewed publications in prestigious journals and 15,000+ citations, his work has gained global recognition. Dr. Wei’s contributions have significantly impacted rheumatology, influencing clinical practices and shaping the future of precision medicine.

🥇Award and Recognition

Dr. James Cheng-Chung Wei, MD, PhD, FACR, has earned global acclaim for his groundbreaking contributions to rheumatology and translational medicine. With an H-index of 45 and over 600 peer-reviewed publications, including works in The Lancet and JAMA, he has garnered more than 15,000 citations. As Editor-in-Chief of the International Journal of Rheumatic Diseases, he has shaped scholarly discourse. Dr. Wei has received numerous accolades for his innovative research and leadership, including his role as president of the Taiwan Medical Big Data Medical Research Society. His extensive involvement with GRAPPA, ASAS, and the American College of Rheumatology underscores his global impact.

Conclusion:

Dr. James Cheng-Chung Wei, MD, PhD, FACR, is a leading figure in clinical immunology and rheumatology, whose groundbreaking contributions have advanced medical science and patient care. With over 600 peer-reviewed publications, 15,000+ citations, and an H-index of 45, his work has earned global recognition. As Editor-in-Chief of the International Journal of Rheumatic Diseases and a leader in international organizations like GRAPPA and ACR, Dr. Wei exemplifies academic excellence and impactful leadership. His dedication to translational research, clinical trials, and big data studies cements his reputation as a visionary in rheumatology and an exceptional candidate for the Best Researcher Award.

📚Publication Top Notes

The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection

Authors: M Rudwaleit, D Van Der Heijde, R Landewé, J Listing, N Akkoc, J Brandt, JCC Wei, …

Citations: 4785

Year: 2009

📑🔬

The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general

Authors: M Rudwaleit, D van der Heijde, R Landewé, N Akkoc, J Brandt, CT Chou, JCC Wei, …

Citations: 2041

Year: 2011

📚🔍

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

Authors: JS Smolen, J Braun, M Dougados, P Emery, O FitzGerald, P Helliwell, JCC Wei, …

Citations: 635

Year: 2014

🌍🩺

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological therapies

Authors: D van der Heijde, JCC Wei, M Dougados, P Mease, A Deodhar, …

Citations: 393

Year: 2018

💉🦠

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

Authors: D van der Heijde, A Deodhar, JC Wei, E Drescher, D Fleishaker, …

Citations: 392

Year: 2017

💊⚖️

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Authors: D Baeten, M Østergaard, JCC Wei, J Sieper, P Järvinen, LS Tam, …

Citations: 373

Year: 2018

🔬💡

Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind study

Authors: M Dougados, D van der Heijde, J Sieper, J Braun, WP Maksymowych, JCC Wei, …

Citations: 264

Year: 2014

🏥🔥

Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks

Authors: W Wang, CY Wang, SI Wang, JCC Wei

Citations: 253

Year: 2022

❤️🦠

Management of gout and hyperuricemia: multidisciplinary consensus in Taiwan

Authors: KH Yu, DY Chen, JH Chen, SY Chen, SM Chen, TT Cheng, SC Hsieh, JCC Wei, …

Citations: 147

Year: 2018

💍⚖️

Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis

Authors: U Kiltz, D Van Der Heijde, A Boonen, N Akkoc, W Bautista-Molano, JCC Wei, …

Citations: 144

Year: 2018

📊💪